Cidara Therapeutics (CDTX) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov[4], including 1 Phase 3[1], 1 Phase 2[2], 1 Phase 1[3].
Trial NCT07159763[5] evaluates CD388 Injection in Influenza with a target enrollment of 7500 participants.
No Form 4 insider filings for CDTX were recorded at the SEC in the past 30 days[6].